Skip to main content
NAMS
NASDAQ Life Sciences

Bain Capital Sells $131.4M in Shares, Drops Below 5% Ownership

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$33.78
Mkt Cap
$4.311B
52W Low
$16.785
52W High
$42.205
52W Position info
101% above low
Off High info
20% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

NAMS has more than doubled off its 52-week low of $16.785.

Summary

Bain Capital Life Sciences has sold $131.4 million in NewAmsterdam Pharma shares, reducing its stake to below 5% beneficial ownership.


Key Events · Ownership and Investor Activity · NAMS

  • Major Stake Reduction

    Bain Capital Life Sciences entities sold 3.5 million Ordinary Shares across three transactions from May 8-12, 2026.

  • Significant Proceeds

    The sales generated aggregate proceeds of approximately $131.4 million, with shares sold at weighted average prices between $37.22 and $39.98.

  • Below 5% Ownership

    Following these sales, Bain Capital Life Sciences collectively ceased to beneficially own 5% or more of NewAmsterdam Pharma's outstanding Ordinary Shares, now holding approximately 3.3%.


Analysis · NAMS · Life Sciences

Bain Capital Life Sciences entities have significantly reduced their stake in NewAmsterdam Pharma, selling approximately $131.4 million worth of shares over three days. This substantial disposition has caused the investment group to cease being a 5% beneficial owner. This marks a major reduction in their position and reinforces a broader distribution trend seen in recent insider activity.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NAMS was trading at $33.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $16.79 to $42.21. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NAMS - Latest Insights

NAMS
Nov 04, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.69
Real-time Price: $18.32 info
Change: -$2.37 (-11%) info
Market Cap: $2.208B info
NAMS
Nov 04, 2026, 7:31 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.24
Real-time Price: $18.32 info
Change: -$1.92 (-9%) info
Market Cap: $2.208B info
NAMS
Sep 29, 2026, 8:22 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.71
Real-time Price: $18.32 info
Change: -$5.39 (-23%) info
Market Cap: $2.208B info
NAMS
Sep 22, 2026, 4:58 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $23.32
Real-time Price: $18.32 info
Change: -$5.00 (-21%) info
Market Cap: $2.208B info
NAMS
Sep 21, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $22.82
Real-time Price: $18.32 info
Change: -$4.50 (-20%) info
Market Cap: $2.208B info